https://www.healio.com/news/ophthalmology/20220207/proficiency-flexibility-help-match-patients-with-appropriate-migs-device
Feb 7th, 2022 - WAIKOLOA, Hawaii — With several good MIGS options, the choice often comes down to matching the procedure with the patient, according to a presentation at Hawaiian Eye 2022. John Berdahl, MD, said devices such as the Hydrus microstent (Ivantis/Alcon) and the iStent (Glaukos) have shown efficacy in reducing IOP and medications in patients with glaucoma. “So, how do you choose?” Berdahl said. “I a...
https://www.healio.com/news/ophthalmology/20220203/lower-bevacizumab-doses-agents-with-less-systemic-exposure-may-be-safer-options-for-rop
Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...
https://www.healio.com/news/ophthalmology/20220121/be-cautious-if-considering-use-of-premium-iols-in-patients-with-glaucoma
Jan 21st, 2022 - WAIKOLOA, Hawaii — Surgeons need to consider the risks and possible refractive outcomes before implanting a premium IOL in a patient with glaucoma, according to a presentation at Hawaiian Eye 2022. Nathan Radcliffe, MD, said that when a patient with glaucoma who already has a premium IOL experiences a problem, the IOL is rarely the issue. “I never remove the premium IOL because as bad as the gl...
https://www.healio.com/news/ophthalmology/20220119/advances-may-ease-difficulties-of-visual-field-testing
Jan 19th, 2022 - WAIKOLOA, Hawaii — Visual field testing is important for detecting progression in patients with glaucoma, but some may have difficulty with the test process, according to a speaker here. “This is very true for the full threshold patterns, which require 15 minutes per eye,” Monica Ertel, MD, PhD, said at Hawaiian Eye 2022. Ertel discussed developments in visual field strategies, including visual...
https://www.healio.com/news/ophthalmology/20210518/holekamp-nm-home-oct-for-monitoring-namd-presented-at-retina-2021-may-814-2021-wailea-hawaii
May 18th, 2021 - WAILEA, Hawaii — The COVID-19 pandemic changed the way physicians monitor age-related macular degeneration, and Nancy M. Holekamp, MD, believes those changes are here to stay. “We all learned that remote monitoring of our patients is desirable, even if there isn’t a pandemic,” she said in her presentation at Retina 2021. “It currently exists with monitoring patients with intermediate AMD, and t...
https://doi.org/10.1002/art.41752
Arthritis & Rheumatology (Hoboken, N.J.); Fraenkel L, Bathon JM et. al.
Jun 9th, 2021 - To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764882
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.
Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat-to-target strategy, and use of imaging. New q...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18f11eed-9ef6-43f6-8db0-720c27563871
Apr 1st, 2023 - Spironolactone tablets are an aldosterone antagonist indicated for: •The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (1.1). •Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfa...
https://www.mdedge.com/psychiatry/article/262165/bipolar-disorder/psychiatric-comorbidities-predict-complex-polypharmacy
Heidi Splete
Mar 31st, 2023 - Complex polypharmacy in patients with bipolar disorder was associated with sociodemographic and clinical features, including older age, single status, and psychiatric comorbidities, based on data from more than 500 individuals. Patients with bipolar disorder (BD) often receive prescriptions for multiple medications to manage a range of medical and psychiatric symptoms, but the definition of pol.
https://www.medpagetoday.com/neurology/alzheimersdisease/103817
Mar 31st, 2023 - Anti-amyloid therapies for Alzheimer's disease accelerated brain atrophy, a systematic review and meta-analysis of MRI data showed. Across 31 clinical trials, brain volume changes were seen for different classes of anti-amyloid agents, reported Scott Ayton, PhD, of the University of Melbourne in Australia, and co-authors in Neurology. The analysis focused mainly on two types of anti-amyloid dru...
https://clinicaltrials.gov/ct2/show/NCT03492775
Mar 31st, 2023 - Study design: This is a randomized, open-label, multicenter phase II trial with a parallel-group design of two groups. Randomization and Interventions: Randomization between Obinutuzumab single agent treatment versus Obinutuzumab plus Bendamustine followed by Obinutuzumab Treatment plans: Arm A: Obinutuzumab single agent Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles ...
https://clinicaltrials.gov/ct2/show/NCT03723564
Mar 31st, 2023 - All women with fetuses having either severe LUTO with intrauterine renal failure or bilateral renal agenesis that meet the inclusion criteria will be invited to participate in this study. For those patients, the actual standard of care is expectant prenatal management or termination of pregnancy (<22 weeks according to law). This study will offer serial amnioinfusions for patients with LUTO or ...
https://clinicaltrials.gov/ct2/show/NCT02840877
Mar 31st, 2023 - A major knowledge gap is the degree to which poor treatment outcomes in alcohol-abusing patients are due to noncompliance alone. Problem alcohol use impacts on retention in care and adherence to daily TB treatment. Poor medication adherence and increased default from TB care have been documented for patients consuming alcohol regularly in several countries. Yet there has been no research to ide...
https://clinicaltrials.gov/ct2/show/NCT04181138
Mar 31st, 2023 - Pediatric primary sclerosing cholangitis (PSC) is a rare autoimmune biliary fibrosing disease that leads to significant morbidity, the need for liver transplantation in ~50% of patients, and an increased risk for biliary and colorectal cancers in adulthood. The progression of the biliary disease in children is variable and risk factors associated with a more rapid progression of disease have no...
https://clinicaltrials.gov/ct2/show/NCT00606346
Mar 31st, 2023 - This registry study will include volunteer pediatric patients: approximately 2,000 pediatric patients with Crohn's Disease who have been treated with infliximab and approximately 2,000 pediatric patients with Crohn's Disease who have received therapies other than infliximab. Approximately 1,000 pediatric patients with Ulcerative Colitis or Indeterminant Colitis will also be enrolled. All patien...
https://clinicaltrials.gov/ct2/show/NCT04970056
Mar 31st, 2023 - The main objective of the PRECEDE Consortium is to build a shared resource to drive research in critical areas necessary for early detection and prevention of PDAC. The PRECEDE Consortium is an observational prospective cohort study, with single or serial biosample collection (every 6-12 months) in defined high-risk groups. A standardized procedure for collection and processing of human blood f...
https://clinicaltrials.gov/ct2/show/NCT04965753
Mar 31st, 2023 - This study is an ascending multiple dose clinical trial with expansion arms. It is primarily intended to evaluate the safety and tolerability of FHD-609 when administered intravenously to subjects with advanced synovial sarcoma or advanced SMARCB1-loss tumors. The Dose Escalation Phase will allow for the determination of the recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) of...
https://clinicaltrials.gov/ct2/show/NCT00061828
Mar 31st, 2023 - This is a multi-center project to establish a prospective database of clinical information and a repository of blood, and tissue samples from children with diagnoses of neonatal liver diseases, such as biliary atresia (BA), idiopathic neonatal hepatitis (INH), and specific neonatal presentations of genetic cholestatic disorders in order to perform research in these important liver problems. Chi...
https://clinicaltrials.gov/ct2/show/NCT04970355
Mar 31st, 2023 - The purpose of this study is to determine the efficacy of erenumab in a loading dose of 280mg followed by 140mg after 4 weeks compared to placebo as a prophylactic treatment in patients with chronic cluster headache. This study has a 10-week 2-arm, randomized, double-blind, parallel- group, placebo-controlled design. Data from this study will provide important information if the blockade of the...
https://clinicaltrials.gov/ct2/show/NCT05192863
Mar 31st, 2023 - This is a non-interventional, prospective study of participants with moderately to severely active CD who are initiating treatment with vedolizumab according to the current summary of product characteristics (SmPC) in the real world setting. The study will enroll approximately 100 participants. The data will be collected prospectively at the study sites and will be recorded into electronic case...
